WVU Cancer Institute patients first in state to receive new lung cancer treatment

MORGANTOWN, W.Va. – The WVU Cancer Institute has become the first in the state to offer Imdelltra (tarlatamab), a pioneering therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). 

Approved by the FDA in May, Imdelltra has shown potential to be a transformative advancement in treating one of the most challenging forms of lung cancer. This targeted therapy is designed to improve outcomes in patients who have tried all other treatment options, offering new possibilities for those with advanced disease. Its introduction at the WVU Cancer Institute reflects the Institute’s mission to provide West Virginians and those from surrounding regions with the highest quality cancer care. 

“Imdelltra is a promising step forward in the fight against lung cancer,” Mohammed Almubarak, M.D., section chief of solid tumors in the Department of Medical Oncology at the WVU Cancer Institute, said. “For patients facing extensive-stage small cell lung cancer, this therapy delivers new hope for improved outcomes and better quality of life.” 

Hannah Hazard-Jenkins, M.D., executive chair and director of the WVU Cancer Institute, emphasized the significance of this achievement for the state and region.  

“As the state’s premier cancer care provider, we are committed to ensuring that West Virginians have access to the most innovative and effective treatments available,” she said. “The introduction of Imdelltra aligns with our goal of leading cancer care advancements and improving outcomes for all our patients.” 

For more information about lung cancer treatments at the WVU Cancer Institute, visit WVUMedicine.org/Cancer.